Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.37 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.35 |
| ▸ | EGFR | P00533 | 4/20 | 0.35 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2494022 | 1.00 | CA2 (0.38) | CA2KCNJ5KCNJ3MAOBMAPK14 | |
| SCHEMBL2503804 | 0.82 | CA2 (0.40) | CA2KCNJ5KCNJ3MAPK14P2RX3 | |
| SCHEMBL2503801 | 0.82 | CA2 (0.40) | CA2KCNJ5KCNJ3MAPK14P2RX3 | |
| SCHEMBL13303952 | 0.79 | CA2 (0.37) | CA2KCNJ5KCNJ3MAPK14P2RX3 | |
| SCHEMBL10817266 | 0.78 | ALDH1A1 (0.43) | CA2MAPK14 | |
| SCHEMBL10815263 | 0.78 | ALDH1A1 (0.43) | CA2MAPK14 | |
| SCHEMBL10815255 | 0.78 | ALDH1A1 (0.43) | CA2MAPK14 | |
| SCHEMBL9685952 | 0.77 | CA2 (0.40) | CA2KCNJ5KCNJ3MAPK14 | |
| SCHEMBL12519657 | 0.76 | CA2 (0.42) | CA2KCNJ5KCNJ3MAPK14P2RX3 | |
| SCHEMBL3340226 | 0.75 | KCNJ5 (0.36) | CA2KCNJ5KCNJ3MAPK14P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370438-A1 | IMIDAZO [1,2A]PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | Exelixis, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010065760-A1 | IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | EXELIXIS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | CA2 3515/4885KCNJ5 403/4885KCNJ3 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.